Accès ouvert
2025
article
OpenAlex
Tugce Guel, Luka de Vos‐Hillebrand, Dagmar Wilsmann‐Theis, Natalija Novak et autres
ABSTRACT We present the case of a 79‐year‐old female patient diagnosed with psoriasis who developed paradoxical drug reactions after administration of anti‐IL17 and anti‐IL‐23 inhibitors. Having shifted towards a rather eczematous phenotype, the patient received an anti‐IL‐4/IL‐3 inhibitor, subsequently developing erythroderma. This …
de
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Tanja Fetter, Dagmar Wilsmann‐Theis, Luka de Vos‐Hillebrand, Natalija Novak et autres
Abstract We report the successful treatment of a patient with refractory follicular lichen planus (LP) with topical ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, which resulted in significant improvement of lesional skin within 1 month of daily use.
de
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Tanja Fetter, Simon Fietz, Maya Bertlich, Christine Braegelmann et autres
Introduction: Over the past decade, immune checkpoint inhibitors such as antibodies against cytotoxicity T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have become an important armamentarium against a broad spectrum of malignancies. However, these specific inhibitors can cause adverse …
de
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Simon Fietz, Anne Fröhlich, Cornelia Mauch, Luka de Vos‐Hillebrand et autres
Introduction: The anti-programmed cell death protein 1 (PD-1) antibody cemiplimab has shown promising results in the treatment of unresectable or metastatic squamous cell carcinoma, however, frequently leads to immune-related adverse events limiting therapy efficacy. Although cutaneous side effects are common, only very …
de
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Luka de Vos‐Hillebrand, Simon Fietz, Philip Hillebrand, Zsófi Kulcsár et autres
The immune-modulating protein CD52 attenuates lymphocyte function and is associated with autoimmune disorders, for example, multiple sclerosis (MS). CD52 represents a therapeutic target in MS and chronic lymphocytic leukemia (CLL). Its expression has prognostic and predictive value in CLL and is prognostic …
de
(code pays fourni par la source)